



## SPECIAL REPORT

## UTP- and ATP-triggered transmitter release from rat sympathetic neurones via separate receptors

<sup>1</sup>Stefan Boehm, Sigismund Huck & \*Peter Illes

Institute of Neuropharmacology, University of Vienna, Waehringerstrasse 13a, A-1090 Vienna, Austria and \*Institute of Pharmacology and Toxicology, University of Leipzig, Haertelstrasse 16-18, D-04107 Leipzig, Germany

In rat cultured sympathetic neurones, UDP, UTP and ATP at micromolar concentrations triggered  $\text{Ca}^{2+}$ -dependent and tetrodotoxin-sensitive [ $^3\text{H}$ ]-noradrenaline release. The overflow evoked by UTP or ATP was similar at  $100 \mu\text{mol l}^{-1}$ , the concentration used in all subsequent experiments. Pre-exposure of the neurones to  $100 \mu\text{mol l}^{-1}$  UTP significantly reduced ensuing secretory effects of UTP but not of ATP. Conversely, pre-exposure to ATP diminished the overflow due to ATP but not that due to UTP. In the presence of  $10 \mu\text{mol l}^{-1}$  pyridoxal-5'-phosphate or  $30 \mu\text{mol l}^{-1}$  suramin, the secretory response to ATP was reduced, but the effect of UTP was unaltered.  $\text{Zn}^{2+}$  ( $10 \mu\text{mol l}^{-1}$ ) reduced the overflow triggered by UTP, but increased the overflow due to ATP. These results indicate the presence of separate receptors for pyrimidine nucleotides and for purine nucleotides which both trigger transmitter release.

**Keywords:** ATP; UTP;  $\text{P}_2$  purinoceptor; pyrimidinoceptor; rat sympathetic neurone; noradrenaline release

**Introduction** One of the subtypes of  $\text{P}_2$  purinoceptors is the  $\text{P}_{2u}$  receptor which is activated by extracellular ATP and UTP (Fredholm *et al.*, 1994). However, the existence of a receptor activated by UTP, but not by ATP has also been postulated (for review see, Seifert & Schultz, 1989). Evidence for such a pyrimidinoceptor has lately been obtained in a glioma cell line (Lazarowski & Harden, 1994), but still awaits experimental confirmation in cultured neurones. Recent electrophysiological data suggested the presence of distinct receptors for ATP and UTP in rat superior cervical ganglia (see e.g. Connolly, 1995).

In primary cultures of rat sympathetic neurones, ATP evokes noradrenaline release by activation of  $\text{P}_2$  purinoceptors (Boehm, 1994). The present study investigates the effects of pyrimidine nucleotides in these cultures and presents evidence for separate receptors for ATP and UTP which both trigger transmitter release.

**Methods** Superior cervical ganglia were dissected from 2 to 6 day old Sprague Dawley rat pups, dissociated, and plated onto 5 mm polystyrol discs coated with collagen as described by Boehm (1994). After 7 days *in vitro*, culture discs were incubated in  $0.03 \mu\text{mol l}^{-1}$  [ $^3\text{H}$ ]-noradrenaline in culture medium with  $1 \text{ mmol l}^{-1}$  ascorbic acid for 60 min and subsequently superfused at a rate of about  $1.0 \text{ ml min}^{-1}$  with a buffer containing ( $\text{mmol l}^{-1}$ ): NaCl 117, KCl 6.0,  $\text{CaCl}_2$  2.0,  $\text{MgCl}_2$  2.0, glucose 20, HEPES 10, fumaric acid 0.5, Na-pyruvate 5.0, ascorbic acid 0.57, adjusted to pH 7.4 with NaOH; the buffer was kept at  $25^\circ\text{C}$ . After 60 min of washout, collection of 4 min superfusate fractions was started. Cultures were stimulated by 60 s exposures to UTP after 72 min of superfusion ( $\text{S}_{\text{UTP}}$ ) and to ATP after 92 min ( $\text{S}_{\text{ATP}}$ ), at concentrations of  $0.1 \mu\text{mol l}^{-1}$  to  $1 \text{ mmol l}^{-1}$ . In a separate series of experiments, neurones were first exposed to UDP (after 72 min) and then to UTP (after 92 min) at  $10 \mu\text{mol l}^{-1}$  to  $1 \text{ mmol l}^{-1}$ . When desensitization was investigated, cultures were pre-exposed to either  $100 \mu\text{mol l}^{-1}$  UTP or ATP from min 72 to 80, and then overflow was triggered by 60 s exposure to  $100 \mu\text{mol l}^{-1}$  UTP or ATP after 92 min of superfusion. Suramin ( $30 \mu\text{mol l}^{-1}$ ), pyridoxal-5'-phosphate ( $10 \mu\text{mol l}^{-1}$ ),  $\text{ZnCl}_2$  ( $10 \mu\text{mol l}^{-1}$ ), or tetrodotoxin ( $1 \mu\text{mol l}^{-1}$ ) were added to, or extracellular  $\text{Ca}^{2+}$  was removed from, the medium after 52 min of superfusion. Thereafter, these changes in the com-

position of the superfusion medium were maintained until the end of experiments. Finally, the radioactivity remaining in the cells was extracted by perchloric acid and sonication, and the radioactivity in extracts and collected fractions was determined by liquid scintillation counting.


The fractional rate of  $^3\text{H}$  outflow was obtained by dividing the radioactivity of a 4 min sample by the total radioactivity of cultures at the beginning of the corresponding 4 min collection period. The rate of outflow per minute was obtained by a subsequent division by 4. Stimulation-evoked overflow was calculated as the difference between the total  $^3\text{H}$  outflow in the fractions during and immediately after stimulation and the estimated basal outflow, which was assumed to decline linearly from the sample preceding stimulation to the sample 8–12 min after the beginning of the stimulus. This difference was expressed as a percentage of the total radioactivity in the cultures at the beginning of the stimulation ( $\text{S}_{\text{UDP}}\%$ ,  $\text{S}_{\text{UTP}}\%$ ,  $\text{S}_{\text{ATP}}\%$ ). All data represent arithmetic means  $\pm$  s.e.mean. Significance of differences was evaluated by the Mann-Whitney-test.

(–)-[Ring-2,5,6- $^3\text{H}$ ]-noradrenaline ( $56.9 \text{ Ci mmol}^{-1}$ ) was obtained from NEN, Dreieich, Germany; ATP- $\text{Na}_2$ , UDP- $\text{Na}$ , UTP- $\text{Na}_3$ , tetrodotoxin, pyridoxal-5'-phosphate were from Sigma, München, Germany; suramin hexasodium salt was a gift from Bayer, Austria.

**Results** Basal  $^3\text{H}$  efflux measured after 68 min of superfusion amounted to  $0.0024 \pm 0.0001 \text{ min}^{-1}$ , corresponding to  $0.0486 \pm 0.0021 \text{ nCi}$  ( $n = 130$ ). This rate of outflow was not altered in the presence of  $30 \mu\text{mol l}^{-1}$  suramin,  $10 \mu\text{mol l}^{-1}$  pyridoxal-5'-phosphate,  $1 \mu\text{mol l}^{-1}$  tetrodotoxin or in the absence of extracellular  $\text{Ca}^{2+}$  (not shown), but slightly increased by  $10 \mu\text{mol l}^{-1}$   $\text{Zn}^{2+}$  ( $0.0028 \pm 0.0002 \text{ min}^{-1}$ ,  $n = 9$ ;  $P < 0.05$ ). Exposure to UDP, UTP or ATP for 60 s caused concentration-dependent increases in  $^3\text{H}$  outflow: UTP was about equipotent to UDP and apparently more potent than ATP (Figure 1a and b). UTP and ATP evoked similar overflow ( $\text{S}_{\text{UTP}}\%$   $2.311 \pm 0.132$ ;  $\text{S}_{\text{ATP}}\%$   $2.089 \pm 0.124$ ;  $n = 20$ ;  $P > 0.05$ ) at a concentration of  $100 \mu\text{mol l}^{-1}$ , which was used in all subsequent experiments.

Pre-exposure to  $100 \mu\text{mol l}^{-1}$  UTP for 8 min markedly reduced subsequent UTP-, but not ATP-evoked overflow. By contrast, 8 min pre-exposure to  $100 \mu\text{mol l}^{-1}$  ATP reduced ATP- but not UTP-evoked overflow (Figure 1c). In the absence of extracellular  $\text{Ca}^{2+}$  ( $n = 6$ ) and in the presence of  $1 \mu\text{mol l}^{-1}$  tetrodotoxin ( $n = 6$ ), either nucleotide failed to induce  $^3\text{H}$  overflow. Suramin ( $30 \mu\text{mol l}^{-1}$ ) diminished ATP-

<sup>1</sup> Author for correspondence.



**Figure 1** Tritium overflow evoked by UDP, UTP and ATP from rat sympathetic neurones labelled with [ $^3\text{H}$ ]-noradrenaline. After labelling, cell cultures were superfused and 4 min fractions of superfusate were collected subsequent to a 60 min washout period. (a) UTP (open columns) and ATP (solid columns), at the concentrations indicated, were included in the medium for 60 s after 72 min (UTP) and 92 min (ATP) of superfusion, respectively. Overflow is presented as % of the total radioactivity in the cultures at the beginning of exposure to nucleotides (S%).  $n = 6$ , with the exception of  $100 \mu\text{mol l}^{-1}$  ( $n = 20$ ). (b) UDP (hatched columns) and UTP (open columns), at the concentrations indicated, were included in the medium for 60 s after 72 min (UDP) and 92 min (UTP) of superfusion, respectively. Results are presented as % of the total radioactivity (S%).  $n = 5-6$ . (c) Overflow evoked by  $100 \mu\text{mol l}^{-1}$  of UTP (left-hand 3 columns) or ATP (right-hand 3 columns) present for 60 s (after 92 min of superfusion) subsequent to pre-exposure to the same concentration of UTP (open columns) or ATP (solid columns) from min 72 to 80. Results are shown as % of the total radioactivity (S%),  $n = 8$  to 9.  $**P < 0.01$ ,  $***P < 0.001$  vs. the corresponding control values (hatched columns; taken from a,  $n = 20$ ); NS no significant difference. (d)  $^3\text{H}$  outflow and UTP- as well as ATP-evoked overflow under control conditions (Con) or in the presence of  $30 \mu\text{mol l}^{-1}$  suramin (Sur),  $10 \mu\text{mol l}^{-1}$  pyridoxal-5'-phosphate (PXP), or  $10 \mu\text{mol l}^{-1}$   $\text{ZnCl}_2$  ( $\text{Zn}^{2+}$ ), added to the medium after 52 min of superfusion. UTP and ATP ( $100 \mu\text{mol l}^{-1}$ ) were applied for 60 s as indicated by the bars;  $n = 6$  to 9, and  $n = 20$  in the case of controls. Significant differences between the overflow evoked by UTP and ATP:  $**P < 0.01$ ,  $***P < 0.001$ , respectively; NS no significant difference.

evoked overflow by approximately 70% ( $S_{\text{ATP}}\%$   $0.675 \pm 0.080$ ;  $n = 6$ ,  $P < 0.001$  vs control), but left the overflow due to UTP unchanged ( $S_{\text{UTP}}\%$   $1.921 \pm 0.275$ ;  $n = 6$ ;  $P > 0.05$ ). Pyridoxal-5'-phosphate ( $10 \mu\text{mol l}^{-1}$ ) reduced ATP-induced overflow by about 90% ( $S_{\text{ATP}}\%$   $0.207 \pm 0.087$ ;  $n = 8$ ;  $P < 0.001$  vs control) but failed to alter UTP-evoked overflow ( $S_{\text{UTP}}\%$   $1.761 \pm 0.350$ ;  $n = 8$ ;  $P > 0.05$ ).  $\text{Zn}^{2+}$  ( $10 \mu\text{mol l}^{-1}$ ) reduced UTP-evoked overflow ( $S_{\text{UTP}}\%$   $1.627 \pm 0.220$ ;  $n = 9$ ;  $P < 0.05$  vs control), but increased ATP-induced overflow ( $S_{\text{ATP}}\%$   $2.801 \pm 0.247$ ;  $n = 9$ ;  $P < 0.05$  vs control; Figure 1d).

**Discussion** Both UTP and ATP elicited [ $^3\text{H}$ ]-noradrenaline release from rat sympathetic neurones in a  $\text{Ca}^{2+}$ -dependent and tetrodotoxin-sensitive manner. In numerous cells, UTP and ATP elicit various actions by activating the same receptor, the  $\text{P}_{2u}$  purinoceptor (Fredholm *et al.*, 1994). In PC12 cells, for example, UTP and ATP mobilise intracellular  $\text{Ca}^{2+}$  via a  $\text{P}_{2u}$  purinoceptor, although activation of this receptor fails to induce catecholamine secretion (Barry & Cheek, 1994). In the present study, UTP and ATP triggered transmitter release, but acted upon separate receptors, as shown by the following: (i)

The secretory response to either UTP or ATP showed homologous desensitization, but not cross-desensitization, i.e. overflow evoked by UTP was significantly reduced after pre-exposure to UTP, but not after pre-exposure to ATP, and *vice versa*; (ii) the P<sub>2</sub> purinoceptor antagonist, suramin (Dunn & Blakeley, 1988) and pyridoxal-5'-phosphate (Trezise *et al.*, 1994) reduced the overflow evoked by ATP, but not that evoked by UTP; (iii) Zn<sup>2+</sup> (10 μmol l<sup>-1</sup>), which enhances ATP-induced currents (Cloues *et al.*, 1993), increased transmitter release evoked by ATP, but reduced the release evoked by UTP.

ATP evokes noradrenaline release from rat cultured sympathetic neurones by eliciting inward currents through P<sub>2x</sub> purinoceptors (Boehm, 1994). UTP, by contrast, does not

evoke inward currents in these neurones (unpublished observation) and induces transmitter release via a distinct receptor. Since UDP, which activates pyrimidinoceptors but not P<sub>2u</sub> purinoceptors (Von Kügelgen & Starke, 1990; Lazarowski & Harden 1994), was about as potent as UTP, rat sympathetic neurones obviously possess pyrimidinoceptors triggering noradrenaline release.

The excellent technical assistance of G. Koth, A. Motejlek and K. Schwarz is gratefully acknowledged. The study was supported by a grant from the 'Verlassenschaft Maria Buss' to S.B.

## References

- BARRY, V.A. & CHEEK, T.R. (1994). Extracellular ATP triggers two functionally distinct calcium signalling pathways in PC12 cells. *J. Cell. Sci.*, **107**, 451–462.
- BOEHM, S. (1994). Noradrenaline release from rat sympathetic neurones evoked by P<sub>2</sub>-purinoceptor activation. *Naunyn-Schmied. Arch. Pharmacol.*, **350**, 454–458.
- CLOUES, R., JONES, S. & BROWN, D.A. (1993). Zn<sup>2+</sup> potentiates ATP-activated currents in rat sympathetic neurones. *Pflüger's Arch.*, **424**, 152–158.
- CONNOLLY, G.P. (1995). Differentiation by pyridoxal-5-phosphate, PPADS and iso-PPADS between responses mediated by UTP and those evoked by α,β-methylene-ATP on rat sympathetic ganglia. *Br. J. Pharmacol.*, **114**, 727–731.
- DUNN, P.M. & BLAKELEY, A.G.H. (1988). Suramin: a reversible P<sub>2</sub>-purinoceptor antagonist in the mouse vas deferens. *Br. J. Pharmacol.*, **93**, 243–245.
- FREDHOLM, B.B., ABBRACHIO, M.P., BURNSTOCK, G., DALY, J.W., HARDEN, T.K., JACOBSON, K.A., LEFF, P. & WILLIAMS, M. (1994). Nomenclature and classification of purinoceptors. *Pharmacol. Rev.*, **46**, 143–156.
- LAZAROWSKI, E.R. & HARDEN, T.K. (1994). Identification of a uridine nucleotide-selective G-protein-linked receptor that activates phospholipase C. *J. Biol. Chem.*, **269**, 11830–11836.
- SEIFERT, R. & SCHULTZ, G. (1989). Involvement of pyrimidinoceptors in the regulation of cell functions by uridine and by uracil nucleotides. *Trends Pharmacol. Sci.*, **10**, 365–369.
- TREZISE, D.J., BELL, N.J., KHAKH, B.S., MICHEL, A.D. & HUMPHREY, P.P.A. (1994). P<sub>2</sub> purinoceptor antagonist properties of pyridoxal-5-phosphate. *Eur. J. Pharmacol.*, **259**, 295–300.
- VON KÜGELGEN, I. & STARKE, K. (1990). Evidence for separate vasoconstriction-mediating nucleotide receptors, both distinct from the P<sub>2x</sub>-receptor, in rabbit basilar artery: a receptor for pyrimidine nucleotides and a receptor for purine nucleotides. *Naunyn-Schmied. Arch. Pharmacol.*, **341**, 538–546.

(Received June 26, 1995  
Accepted August 3, 1995)